Early results of human atrial natriuretic peptide infusion in non-dialysis patients with chronic kidney disease undergoing isolated coronary artery bypass grafting: The NU-HIT trial for CKD-II

Annals of Thoracic and Cardiovascular Surgery

Volumn 20, Issue 3, 2014, Pages 217-222

  Sezai, Akira ^a   Nakata, Kin Ichi ^a   Iida, Mitsuru ^a   Yoshitake, Isamu ^a   Wakui, Shinji ^a   Hata, Hiroaki ^a   Shiono, Motomi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CPB physiology pathophysiology; Kidney; Surgery complications

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; NPPA PROTEIN, HUMAN; URINARY TRACT AGENT;

BLOOD; CARDIOPULMONARY BYPASS; COMPLICATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HUMAN; INFUSION; JAPAN; KIDNEY; METABOLISM; NATRIURESIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; TREATMENT OUTCOME; URINE;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; HUMANS; INFUSIONS, PARENTERAL; JAPAN; KIDNEY; NATRIURESIS; RENAL AGENTS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903214479     PISSN: 13411098     EISSN: 21861005     Source Type: Journal    
DOI: 10.5761/atcs.oa.13.02252     Document Type: Article

References (28)

1. Hage FG, Venkataraman R, Zoghbi GJ, et al. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009; 53: 2129-40.
2. Di Angelantonio E, Chowdhury R, Sarwar N, et al. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 2010; 341: c4986.
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
4. Hannan EL, Wu C, Bennett EV, et al. Risk stratification of in-hospital mortality for coronary artery bypass graft surgery. J Am Coll Cardiol 2006; 47: 661-8.
5. Chonchol MB, Aboyans V, Lacroix P, et al. Longterm outcomes after coronary artery bypass grafting: preoperative kidney function is prognostic. J Thorac Cardiovasc Surg 2007; 134: 683-9.
6. Hillis GS, Croal BL, Buchan KG, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 2006; 113: 1056-62.
7. Ishani A, Nelson D, Clothier B, et al. The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med 2011; 171: 226-33.
8. Devbhandari MP, Duncan AJ, Grayson AD, et al. Effect of risk-adjusted, non-dialysis-dependent renal dysfunction on mortality and morbidity following coronary artery bypass surgery: a multi-centre study. Eur J Cardiothorac Surg 2006; 29: 964-70.
9. Durmaz I, Büket S, Atay Y, et al. Cardiac surgery with cardiopulmonary bypass in patients with chronic renal failure. J Thorac Cardiovasc Surg 1999; 118: 306-15.
10. Sezai A, Shiono M, Orime Y, et al. Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 2000; 69: 732-8.
11. Sezai A, Hata M, Niino T, et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 2010; 55: 1844-51.
12. Sezai A, Hata M, Niino T, et al. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study. J Am Coll Cardiol 2009; 54: 1058-64.
13. Sezai A, Hata M, Niino T, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol 2011; 58: 897-903.
14. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-92.
15. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-93.
16. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-6.
17. Kasama S, Furuya M, Toyama T, et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008; 29: 1485-94.
18. Maack T, Marion DN, Camargo MJ, et al. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs. Am J Med 1984; 77: 1069-75.
19. Marin-Grez M, Briggs JP, Schubert G, et al. Dopamine receptor antagonists inhibit the natriuretic response to atrial natriuretic factor (ANF). Life Sci 1985; 36: 2171-6.
20. Fett DL, Cavero PG, Burnett JC. Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure. J Am Soc Nephrol 1993; 4: 162-7.
21. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004; 109: 1680-5.
22. Sica D, Oren RM, Gottwald MD, et al. Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction. Clin Cardiol 2010; 33: 330-6.
23. Woo EB, Tang AT, el-Gamel A, et al. Dopamine therapy for patients at risk of renal dysfunction following cardiac surgery: science or fiction? Eur J CardioThorac Surg 2002; 22: 106-11.
24. Lassnigg A, Donner E, Grubhofer G, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11: 97-104.
25. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-43.
26. Holmes CL, Walley KR. Bad medicine: low-dose dopamine in the ICU. Chest 2003; 123: 1266-75.
27. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17-22.
28. McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301-7.